References
- Chaudhary S, Ganguly S, Palanichamy JK, Singh A, Pradhan D, Bakhshi R,
Chopra A, Bakhshi S. Mitochondrial gene expression signature predicts
prognosis of pediatric acute myeloid leukemia patients. Front Oncol.
2023 Feb 9;13:1109518. doi: 10.3389/fonc.2023.1109518. PMID: 36845715
- Madney Y, Aboubakr S, Khedr R, Hafez H, Ahmed N, Elsheshtawy K,
Elanany M, Salahelden A, Shalaby L, Galal Behairy O.
Carbapenem-Resistant Enterobacteriaceae (CRE) among Children
with Cancer: Predictors of Mortality and Treatment Outcome.
Antibiotics (Basel). 2023 Feb 17;12(2):405. doi:
10.3390/antibiotics12020405. PMID: 36830314
- Cerrano M, Bonifacio M, Olivi M, Curti A, Malagola M, Dargenio M,
Scattolin AM, Papayannidis C, Forghieri F, Gurrieri C, Tanasi I,
Zappasodi P, La Starza R, Fracchiolla NS, Chiusolo P, Giaccone L, Del
Principe MI, Giglio F, Defina M, Favre C, Rizzari C, Castella B,
Pizzolo G, Ferrara F, Chiaretti S, Foà R. Daratumumab with or without
chemotherapy in relapsed and refractory acute lymphoblastic leukemia.
A retrospective observational Campus ALL study. Haematologica. 2022
Apr 1;107(4):996-999. doi: 10.3324/haematol.2021.279851.
- Keyhani, A. et al. Increased CD38 expression is associated with
favorable prognosis in adult acute leukemia. Leuk Res. 24, 153–159
(2000)
- Jeyaraman P, Bhasin A, Dayal N, Pathak S, Naithani R. Daratumumab in
dialysis-dependent multiple myeloma. Blood Res. 2020 Mar;55(1):65-67.
doi: 10.5045/br.2020.55.1.65.
- Farber M, Chen Y, Arnold L, Möllmann M, Boog-Whiteside E, Lin YA,
Reinhardt HC, Dührsen U, Hanoun M. Targeting CD38 in acute myeloid
leukemia interferes with leukemia trafficking and induces
phagocytosis. Sci Rep. 2021 Nov 11;11(1):22062. doi:
10.1038/s41598-021-01300-8. PMID: 34764342; PMCID: PMC8586007.
- Vakrmanová B, Nováková M, Říha P, Žaliová M, Froňková E, Mejstříková
E, Starý J, Hrušák O, Šrámková L. CD38: A target in
relapsed/refractory acute lymphoblastic leukemia-Limitations in
treatment and diagnostics. Pediatr Blood Cancer. 2022
Sep;69(9):e29779. doi: 10.1002/pbc.29779. Epub 2022 May 20. PMID:
35592935.
- J. Krejcik, T. Casneuf, I.S. Nijhof, B. Verbist, J. Bald, T. Plesner,
K. Syed, K. Liu, N.W. van de Donk, B.M. Weiss, T. Ahmadi, H.M.
Lokhorst, T. Mutis, A.K. Sasser, Daratumumab depletes CD38+ immune
regulatory cells, promotes T-cell expan- sion, and skews T-cell
repertoire in multiple myeloma, Blood 128 (3) (2016) 384–394.
- Klimentova M, Shelikhova L, Ilushina M, Kozlovskaya S, Blagov S, Popov
A, Kashpor S, Fadeeva M, Olshanskaya J, Glushkova S, Pershin D,
Balashov D, Maschan A, Maschan M. Targeted Therapy With Venetoclax and
Daratumumab as Part of HSCT Preparative Regimen in Children With
Chemorefractory Acute Myeloid Leukemia. Transplant Cell Ther. 2023
Feb;29(2):127.e1-127.e9. doi: 10.1016/j.jtct.2022.11.022.